|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| {{drugbox |
| | #REDIRECT [[Irbesartan#Pharmacology]] |
| |width=200px
| |
| |image=Irbesartan_structure.png
| |
| |IUPAC_name = 2-butyl-<br />3-[''p''-(''o''-1''H''-tetrazol-5-ylphenyl)benzyl]-<br />1,3-diazaspiro[4.4]non-1-en-4-one
| |
| |CAS_number = 138402-11-6
| |
| | ATC_prefix = C09
| |
| | ATC_suffix = CA04
| |
| | PubChem = 3749
| |
| | DrugBank = APRD00413
| |
| | C=25 | H=28 | N=6 | O=1
| |
| |molecular_weight = 428.53
| |
| |bioavailability = 60–80%
| |
| |metabolism = [[Hepatic]] ([[CYP2C9]])
| |
| |elimination_half-life = 11–15 hours
| |
| |excretion = [[Renal]] 20%, [[feces|faecal]] 65%
| |
| | licence_EU = Aprovel
| |
| | licence_US = Irbesartan
| |
| |pregnancy_category = D <small>([[Australia|Au]])</small>
| |
| |legal_status = S4 <small>(Au)</small>, POM <small>(UK)</small>, ℞-only <small>(U.S.)</small>
| |
| |routes_of_administration = Oral
| |
| }}
| |
| __NOTOC__
| |
| {{CMG}}
| |
| | |
| | |
| | |
| ==[[Irbesartan (patient information)|For patient information, click here]]==
| |
| | |
| '''Irbesartan''' (INN) ({{pronEng|ɜrbəˈsɑrtən}}) is an [[angiotensin II receptor antagonist]] used mainly for the treatment of [[hypertension]]. Irbesartan was developed by Sanofi Research (now part of [[sanofi-aventis]]). It is jointly marketed by [[sanofi-aventis]] and [[Bristol-Myers Squibb]] under the trade names '''Aprovel''', '''Karvea''', and '''Avapro'''.
| |
| | |
| ==Clinical use==
| |
| {{dablink|Main article: [[Angiotensin II receptor antagonist]]}}
| |
| | |
| ===Indications===
| |
| As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of [[hypertension]]. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes,<ref name="Lewis-2001">{{cite journal | author=Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. | title=Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. | journal=N Engl J Med | year=2001 | volume=345 | issue=12 | pages=851-60 | id=PMID 11565517}}</ref> hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).<ref name="Rossi2006">Rossi S, editor. [[Australian Medicines Handbook]] 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3</ref>
| |
| | |
| ===Combination with diuretic===
| |
| Irbesartan is also available in a combination formulation with a low dose [[thiazide diuretic]], invariably [[hydrochlorothiazide]], to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including '''CoAprovel''', '''Karvezide''', '''Avalide''' and '''Avapro HCT'''.
| |
| | |
| ==References==
| |
| {{reflist}}
| |
| | |
| ==See also==
| |
| *[[Angiotensin II receptor antagonist]]
| |
| | |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| | |
| [[Category:angiotensin II receptor antagonists]]
| |
| [[Category:Drugs]]
| |
| | |
| [[hu:Irbesartan]]
| |
| [[pt:Irbesartan]] | |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |